Neoadjuvant SF-SBRT Plus Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC.

Inclusion Criteria: * Male or female participants aged 18 to 75 years; * Eastern Cooperative Oncology Group performance status of 0 or 1; * Previously untreated, pathologically confirmed, resectable or potentially -resectable stage II, IIIA, or IIIB (N2) non-small cell lung cancer according to the 8th edition of the American Joint Committee on Cancer staging system; * At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors version 1.1; * Adequate pulmonary function, as assessed by the surgeon, to tolerate the planned lung resection; * Absence of sensitizing EGFR mutations or ALK rearrangements confirmed by tissue-based molecular pathological testing; * Adequate organ function, defined as follows: Bone marrow function: absolute neutrophil count ≥1.5 × 10\^9/L, platelet count ≥80 × 10\^9/L, and hemoglobin ≥9 g/dL; Liver function: total serum bilirubin ≤1.5 × upper limit of normal; alanine aminotransferase and aspartate aminotransferase ≤1.5 × upper limit of normal; Renal function: serum creatinine ≤1.5 × upper limit of normal or creatinine clearance ≥60 mL/min, and blood urea nitrogen ≤200 mg/L; * Participants must be fully informed about the study and voluntarily sign the written informed consent form. * Male participants with reproductive potential or female participants of childbearing potential must agree to use effective contraception during the study, such as oral contraceptives, an intrauterine device, or a barrier method combined with…